 |
| |
| Dec-13-19 | Upgrade |
Credit Suisse |
Underperform → Neutral |
$260 → $300 |
|
| Dec-02-19 | Downgrade |
Robert W. Baird |
Neutral → Underperform |
|
|
| Nov-12-19 | Initiated |
SunTrust |
Buy |
$337 |
|
| Nov-01-19 | Downgrade |
Standpoint Research |
Buy → Hold |
|
|
| Oct-30-19 | Upgrade |
Bernstein |
Mkt Perform → Outperform |
|
|
| Oct-23-19 | Upgrade |
SVB Leerink |
Mkt Perform → Outperform |
$256 → $350 |
|
| Oct-23-19 | Upgrade |
Guggenheim |
Neutral → Buy |
$256 → $365 |
|
| Oct-23-19 | Reiterated |
H.C. Wainwright |
Buy |
$300 → $335 |
|
| Oct-23-19 | Reiterated |
BofA/Merrill |
Underperform |
$200 → $235 |
|
| Oct-17-19 | Resumed |
BofA/Merrill |
Underperform |
$200 |
|
| Jun-28-19 | Downgrade |
Piper Jaffray |
Overweight → Neutral |
$280 → $250 |
|
| Jun-05-19 | Upgrade |
Standpoint Research |
Hold → Buy |
|
|
| May-23-19 | Resumed |
Citigroup |
Neutral |
|
|
| May-23-19 | Initiated |
Wedbush |
Neutral |
|
|
| May-21-19 | Initiated |
Credit Suisse |
Underperform |
$198 |
|
| Apr-10-19 | Resumed |
Raymond James |
Mkt Perform |
|
|
| Mar-25-19 | Reiterated |
H.C. Wainwright |
Buy |
$363 → $300 |
|
| Mar-22-19 | Reiterated |
BMO Capital Markets |
Market Perform |
$322 → $250 |
|
| Mar-22-19 | Downgrade |
UBS |
Buy → Neutral |
$395 → $242 |
|
| Mar-22-19 | Downgrade |
Morgan Stanley |
Overweight → Underweight |
$401 → $210 |
|
|
|
| Jan-23-20 09:21AM | The one value strategy that wasnt a disaster now favors commodity sector over techs MarketWatch |
| 08:51AM | Roche's Risdiplam Meets Primary Endpoint in Infants Study Zacks |
| 01:18AM | Roche's risdiplam meets primary endpoint in trial of SMA drug in infants Reuters |
| Jan-21-20 06:21PM | Novartis (NVS) Gets Approval for MS Drug Mayzent in Europe Zacks |
| 02:50PM | Mass. employers earn high marks in LGBTQ-friendly workplace index American City Business Journals |
| Jan-20-20 05:32PM | Top Long-Term Growth Stocks in the Health Care Sector GuruFocus.com |
| Jan-16-20 01:10PM | FDA Risks Sacrificing Its Standards for Speed Bloomberg |
| 05:00AM | Top Picks 2020- Ionis Pharmaceuticals IONS MoneyShow |
| Jan-15-20 05:50PM | 4 High-Quality Health Care Companies for 2020 GuruFocus.com |
| 05:39AM | Alexion pushes 'high-risk, high-reward' ALS strategy amid competitive pressure American City Business Journals |
| Jan-14-20 01:02PM | Biogen Inc. -- Moody's announces completion of a periodic review of ratings of Biogen Inc. Moody's |
| 09:55AM | Biogen Acquires Early-Stage CNS Drug From Pfizer for $75M Zacks |
| Jan-13-20 08:46AM | Benzinga Pro's Top 5 Stocks To Watch For Mon., Jan. 13, 2020: WCC, LULU, XLF, TEAM, BIIB Benzinga |
| 07:51AM | Biogen to buy from Pfizer an asset to develop into potential Alzheimer's, Parkinson's treatments MarketWatch |
| 07:30AM | Biogen to Acquire Novel Clinical Stage Asset with Application in Alzheimers Disease and Parkinsons Disease from Pfizer Inc. GlobeNewswire |
| Jan-10-20 08:05PM | Biogen Defends Its Blockbuster Against Mylans Patent Challenge Barrons.com |
| 07:00AM | Biogen signs neuro disease drug deal with Cambridge startup American City Business Journals |
| Jan-09-20 09:20AM | 4 Things to Pay Attention to at the J.P. Morgan Health-Care Conference Next Week Barrons.com |
| 08:00AM | Red-Hot Biotech Stocks Brace For Key Meeting Here's What To Expect Investor's Business Daily |
| Jan-08-20 07:30AM | Behind the Seizure® Program Further Expands Access to Genetic Testing for Children to Speed the Diagnosis of Genetic Epilepsy PR Newswire |
| Jan-07-20 11:00AM | Top Health Care Stocks for January 2020 Investopedia |
| 08:00AM | Is Biogen Stock A Buy On Renewed Hope In Alzheimer's Disease? Investor's Business Daily |
| Jan-06-20 09:38AM | Biogen Faces a Looming Patent Decision. Heres How Much Its Stock Could Drop If It Loses. Barrons.com |
| Jan-02-20 10:08AM | Drug-Price Increases Show Business as Usual Despite Public Pressure Barrons.com |
| 08:41AM | Bristol-Myers, Gilead, Biogen, Other Drugmakers Increased U.S. List Prices on Jan. 1: Report TheStreet.com |
| Jan-01-20 11:47AM | More drugmakers hike U.S. prices as new year begins Reuters |
| Dec-30-19 11:02AM | Why Biogen Inc. (NASDAQ:BIIB) Looks Like A Quality Company Simply Wall St. |
| Dec-26-19 11:14AM | 2020 Vision: In Biogen, industry could see 1st new Alzheimer's drug in years American City Business Journals |
| Dec-25-19 08:20PM | How Did Biogen Inc. (BIIB) Compare Against Top Hedge Fund Stocks in 2019? Insider Monkey |
| Dec-24-19 07:00AM | Heres to Your Health: A Decade of Drug Breakthroughs Bloomberg |
| Dec-23-19 02:47PM | Investors flock to neuro drug makers after FDA approves new schizophrenia drug MarketWatch |
| Dec-21-19 11:24AM | Barron's Picks And Pans: Alibaba, Biogen, China Mobile, Peter Lynch Picks And More Benzinga |
| 08:00AM | Biogen Announced a Big Stock Buyback. It May Not Be a Great Use of Cash. Barrons.com |
| Dec-20-19 12:00PM | Stock Upgrades: Biogen Shows Rising Relative Strength Investor's Business Daily |
| 08:03AM | Dow Jones Futures: Nike, Biogen, Winnebago Lead 5 Stocks Near Buy Points Moving On News Investor's Business Daily |
| 05:00AM | Biogen- What's Next in Alzheimer's Research MoneyShow |
| 04:37AM | Biogen Climbs on $5 billion Share Buyback Program TheStreet.com |
| Dec-19-19 05:07PM | Biogen Stock Is Jumping After Announcing a $5 Billion Share Buyback Barrons.com |
| 10:13AM | The Zacks Analyst Blog Highlights: Amarin, Amgen, Gilead Sciences, Biogen and Kiniksa Pharmaceuticals Zacks |
| 10:01AM | AbbVie's JAK Inhibitor Rinvoq Receives Approval for RA in EU Zacks |
| 08:00AM | Catalyst Biosciences Announces Global License and Collaboration Agreement to Develop Pegylated CB 2782 for the Treatment of Dry Age-Related Macular Degeneration GlobeNewswire |
| 07:05AM | Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)? Zacks |
| Dec-18-19 05:52PM | 3 'Magic Formula' Companies Investing in Growth GuruFocus.com |
| 05:30PM | 5 Attractive Christmas Deals: Stocks With High Value and Quality GuruFocus.com |
| 02:27PM | Biotech Stock Roundup: AMRN Stock Up, Pipeline Updates from GILD, BIIB, AMGN & More Zacks |
| Dec-16-19 08:05AM | Biogen's Gosuranemab Fails in Phase II Brain Disorder Study Zacks |
| Dec-13-19 10:29AM | Biotech Stocks Are Poised to Rise in 2020, Analyst Says. Here Is His Top Pick. Barrons.com |
| 07:40AM | Biogen to discontinue development of treatment for rare brain disorder after trial misses goals MarketWatch |
| 07:30AM | Biogen Reports Top-Line Results from Phase 2 Study in Progressive Supranuclear Palsy GlobeNewswire |
| Dec-09-19 11:10AM | Investors Are Moving Back Into Resurgent Biotech ETFs ETF Trends |
| 09:42AM | J&J Presents Data on CAR-T Therapy Drug and Imbruvica at ASH Zacks |
| Dec-08-19 12:29PM | Bulls And Bears Of The Week: Facebook, Intel, Netflix, Tesla And More Benzinga |
| Dec-06-19 04:31PM | Biogen Edges Near Breakout But Will Its Alzheimer's Drug Pass Muster? Investor's Business Daily |
| 03:08PM | Alzheimers expert says more clinical trials are needed for controversial Biogen drug MarketWatch |
| 11:52AM | Biogen CEO on Controversial Alzheimers Drug: There Is Hope Meredith Videos |
| 11:19AM | Risks of Biogen Alzheimers Drug Are Clear, but Its Benefits Are Still Unproven, Says Raymond James Barrons.com |
| 10:58AM | Cassava stock is up on Alzheimer's data MarketWatch |
| 10:22AM | Money Is Moving Back Into Surging Biotech Funds Barrons.com |
| 09:55AM | Biogen Analysts Divided Over Alzheimer's Drug Following CTAD Presentation Benzinga |
| 09:30AM | Biogen Up on New Data on Alzheimer's Candidate Aducanumab Zacks |
| Dec-05-19 08:50PM | After Biogen's big Alzheimer's drug data reveal, observers remain divided American City Business Journals |
| 07:35PM | Eisai, Partner Biogen Gain as Alzheimers Drug Studies Revived Bloomberg |
| 04:32PM | Astellas-Audentes Deal Likely to Ignite More Acquisitions GuruFocus.com |
| 04:07PM | Biogen Stock Pops: Here's What Happened In Its Alzheimer's Update Investor's Business Daily |
| 04:06PM | Biogen Stock Is Rising After a Presentation at an Alzheimers Conference Barrons.com |
| 02:50PM | Wild Biotech Day Sparks $7.6 Billion Shuffle for Neurology Trio Bloomberg |
| 02:19PM | Biogen stock climbs as investors shrug off analyst skepticism about Alzheimers drug MarketWatch |
| 02:01PM | Biogen's CTAD Presentation On Aducanumab Elicits Mixed Response Benzinga |
| 01:44PM | Biogen Has More Hope Than Data for Alzheimers Drug Bloomberg |
| 12:56PM | The Dow Goes Negative Despite a Glimmer of Hope on Trade Barrons.com |
| 12:22PM | Biogen shares rise on Alzheimer's candidate data MarketWatch |
| 10:08AM | Biotech Stocks Are Making Wild Moves Amid a Deluge of Trial Data Barrons.com |
| 09:51AM | UPDATE 1-Novartis R&D boss says doesn't see big opportunity in oral SMA therapy Reuters |
| 08:51AM | Aurinia's Lupus Candidate Succeeds in Pivotal Study, Stock Up Zacks |
| 08:15AM | Biogen Shares Up After Alzheimer Drug Tests Show No New Concerns TheStreet.com |
| 06:00AM | Biogen to make case to skeptics for its controversial Alzheimer's drug Reuters |
| 02:00AM | OPEC, Huawei, PG&E, Biogen, and a 2020 Recession? - 5 Things You Must Know TheStreet.com |
| Dec-04-19 10:25AM | Biogen's Lupus Candidate Meets Endpoint in Phase II Study Zacks |
| 10:13AM | Anavex shares rise in advance of Alzheimer's meeting MarketWatch |
| 10:02AM | Biotech Stock Roundup: Pipeline Updates From BIIB, AXSM, CARA, Collaborations & More Zacks |
| Dec-03-19 11:22AM | Cramer Weighs In On Biogen, Caterpillar And More Benzinga |
| 09:29AM | Biogen's Shares Down on Rating Downgrade by Baird Analyst Zacks |
| 09:26AM | Where to Buy Booming Biotech ETFs Investopedia |
| 07:30AM | Biogen Announces Positive Phase 2 Study Results for Cutaneous Lupus Erythematosus (CLE) and Systemic Lupus Erythematosus (SLE) GlobeNewswire |
| Dec-02-19 04:13PM | Biogen Stock Is Facing A Crucial Test Here's What You Need To Know Investor's Business Daily |
| 01:56PM | Biogen's shares drop on critical view of Alzheimer's data MarketWatch |
| 01:55PM | Biogen's Alzheimer's Drug 'Falls Far Short Of Compelling Argument For Approval,' Baird Says In Downgrade Benzinga |
| 10:25AM | Biogens Alzheimers Drug Wont Get Approved, Analyst Says Barrons.com |
| 09:48AM | Biogen Downgraded by Baird Analyst Over Move to Salvage Alzheimers Drug Bloomberg |
| 06:24AM | Have Insiders Been Buying Biogen Inc. (NASDAQ:BIIB) Shares? Simply Wall St. |
| Dec-01-19 09:30AM | The Week Ahead In Biotech: ASH 2019 Gets Underway, Biogen's Aducanumab Data And More Benzinga |
| Nov-28-19 10:24PM | Hedge Funds Warming Up To Biogen Inc. (BIIB) Again Insider Monkey |
| 07:00AM | The 3 Worst-Performing Health Care Stocks of 2019 So Far Barrons.com |
| Nov-27-19 10:09AM | Biotech Stock Roundup: CBAY Falls, CCXI Gains, Amgen Acquires Otezla & More Zacks |
| 08:52AM | ChemoCentryx Up on Encouraging Rare Disease Candidate Data Zacks |
| 08:24AM | The Zacks Analyst Blog Highlights: Vertex, Biogen, BioMarin and Alexion Zacks |
| 06:52AM | Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)? Zacks |
| Nov-26-19 06:07AM | 4 Big Drug Stocks Ripe for Takeover After NVS-MDCO Deal Zacks |
| Nov-25-19 04:59PM | Roche's NDA for SMA Drug Risdiplam Gets Priority Review Zacks |
| 02:45PM | Biogen Sees Its Composite Rating Rise To 97 Investor's Business Daily |
|
|
|
|
| Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases worldwide. The company offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of multiple sclerosis (MS); SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM for the treatment of plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; FLIXABI, an infliximab biosimilar referencing REMICADE; and IMRALDI, an adalimumab biosimilar referencing HUMIRA. In addition, the company offers RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for the treatment of primary progressive MS and relapsing MS, and other anti-CD20 therapies. Further, it is involved in developing BIIB098, Opicinumab, and BIIB061 for MS and neuroimmunology; Aducanumab, Elenbecestat, BAN2401, BIIB092, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB092 and BIIB054 for treating Parkinson's disease and movement disorders; BIIB067, BIIB078, and BIIB110 to treat neuromuscular disorders; BIIB093, TMS-007, and Natalizumab to treat acute neurology; BIIB104 for treating neurocognitive disorders; BIIB074 and BIIB095 for pain; and Dapirolzumab pegol, BG00011, and BIIB059 for treating other diseases, which are under various stages of development. The company offers products through its sales force and marketing groups. Biogen Inc. has collaboration agreements with Genentech, Inc., Eisai Co., Ltd., Alkermes Pharma Ireland Limited, Bristol-Myers Squibb Company, Acorda Therapeutics, Inc., AbbVie Inc., C4 Therapeutics, University of Pennsylvania, Applied Genetic Technologies Corporation, and others. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts. |
|
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| CAPELLO JEFFREY D | EVP & Chief Financial Officer | Jan 02 | Option Exercise | 0.00 | 1,302 | 0 | 2,219 | Jan 06 04:14 PM | | Kramer Robin | VP, Chief Accounting Officer | Dec 03 | Option Exercise | 0.00 | 84 | 0 | 175 | Dec 05 04:24 PM | | Posner Brian S | Director | Dec 02 | Sale | 292.35 | 1,055 | 308,429 | 6,995 | Dec 03 05:58 PM | | Guindo Chirfi | EVP Glob. Prod Strat and Comm | Dec 01 | Option Exercise | 0.00 | 543 | 0 | 2,855 | Dec 03 05:59 PM | | Gregory Ginger | EVP, Human Resources | Aug 01 | Option Exercise | 0.00 | 179 | 0 | 2,295 | Aug 05 04:20 PM | | Karp Daniel | EVP, Corporate Development | Jul 02 | Option Exercise | 0.00 | 196 | 0 | 322 | Jul 05 04:51 PM | | Ehlers Michael D | EVP, Research and Development | Jun 01 | Option Exercise | 0.00 | 1,126 | 0 | 8,525 | Jun 04 04:56 PM | | Vounatsos Michel | Chief Executive Officer | May 02 | Option Exercise | 0.00 | 1,480 | 0 | 22,487 | May 06 04:20 PM | | DENNER ALEXANDER J | Director | May 02 | Buy | 231.24 | 38,000 | 8,787,120 | 643,000 | May 02 05:06 PM | | DENNER ALEXANDER J | Director | May 01 | Buy | 229.46 | 30,000 | 6,883,800 | 605,000 | May 02 05:06 PM | | Vounatsos Michel | Chief Executive Officer | May 01 | Buy | 231.48 | 4,351 | 1,007,169 | 21,007 | May 02 04:30 PM | | DENNER ALEXANDER J | Director | Apr 30 | Buy | 229.25 | 50,342 | 11,540,904 | 575,000 | May 02 05:06 PM | | PANGIA ROBERT W | Director | Mar 18 | Option Exercise | 52.22 | 6,114 | 319,273 | 24,701 | Mar 19 04:08 PM | | PANGIA ROBERT W | Director | Mar 18 | Sale | 328.55 | 6,114 | 2,008,755 | 18,587 | Mar 19 04:08 PM | | McKenzie Paul | EVP Pharmaceutical Oper & Tech | Mar 01 | Option Exercise | 0.00 | 568 | 0 | 7,488 | Mar 05 04:17 PM | | ALEXANDER SUSAN H | EVP Chief Legal Officer & Sec. | Feb 22 | Option Exercise | 38.51 | 8,058 | 310,285 | 36,085 | Feb 26 05:09 PM | | Sandrock Alfred | EVP, Chief Medical Officer | Feb 22 | Option Exercise | 0.00 | 1,663 | 0 | 11,148 | Feb 26 05:07 PM | | Vounatsos Michel | Chief Executive Officer | Feb 15 | Option Exercise | 0.00 | 5,269 | 0 | 18,914 | Feb 20 06:10 PM | | Sandrock Alfred | EVP, Chief Medical Officer | Feb 15 | Option Exercise | 0.00 | 1,318 | 0 | 10,071 | Feb 20 06:08 PM | | McKenzie Paul | EVP Pharmaceutical Oper & Tech | Feb 15 | Option Exercise | 0.00 | 1,448 | 0 | 7,968 | Feb 20 06:07 PM | | Ehlers Michael D | EVP, Research and Development | Feb 15 | Option Exercise | 0.00 | 1,685 | 0 | 8,526 | Feb 20 05:54 PM | | ALEXANDER SUSAN H | EVP Chief Legal Officer & Sec. | Feb 15 | Option Exercise | 0.00 | 1,685 | 0 | 28,776 | Feb 20 05:53 PM | | Vounatsos Michel | Chief Executive Officer | Feb 12 | Option Exercise | 0.00 | 6,899 | 0 | 16,267 | Feb 14 06:33 PM | | Sandrock Alfred | EVP, Chief Medical Officer | Feb 12 | Option Exercise | 0.00 | 4,643 | 0 | 9,452 | Feb 14 06:29 PM | | McKenzie Paul | EVP Pharmaceutical Oper & Tech | Feb 12 | Option Exercise | 0.00 | 3,062 | 0 | 7,059 | Feb 14 06:17 PM | | Gregory Ginger | EVP, Human Resources | Feb 12 | Option Exercise | 0.00 | 1,836 | 0 | 2,561 | Feb 14 06:10 PM | | Ehlers Michael D | EVP, Research and Development | Feb 12 | Option Exercise | 0.00 | 3,827 | 0 | 7,639 | Feb 14 06:07 PM | | ALEXANDER SUSAN H | EVP Chief Legal Officer & Sec. | Feb 12 | Option Exercise | 0.00 | 3,268 | 0 | 27,710 | Feb 14 06:04 PM | | DENNER ALEXANDER J | Director | Feb 01 | Buy | 328.45 | 7,000 | 2,299,163 | 524,658 | Feb 01 04:19 PM | | DENNER ALEXANDER J | Director | Jan 31 | Buy | 330.52 | 25,800 | 8,527,393 | 517,658 | Feb 01 04:19 PM | | DENNER ALEXANDER J | Director | Jan 30 | Buy | 324.86 | 30,000 | 9,745,851 | 491,858 | Feb 01 04:19 PM |
|
|
|
|
|
|
